In a meta-analysis of 24 studies regarding the concomitant use of CDDP and aspirin for the treatment of angina pectoris of CHD, a total of 2275 patients were included.
One hundred and two patients with unstable angina pectoris were randomized into three groups: CDDP group ( n = 33), clopidogrel group ( n = 35), and combination group ( n = 34).
One hundred and twenty elderly patients with silent ischemia were randomized to receive CDDP in the treatment group and isosorbide dinitrate in the control group.
Eighty patients with cardiac syndrome X were randomly assigned to the CDDP group ( n = 40) and control group ( n = 40).
Clinical studies have proved that CDDP can be used to relieve angina pectoris with better effect as an add-on to conventional therapy.[sup],
One hundred and thirty patients with newly diagnosed diabetes were randomized to receive antidiabetic and antihypertensive therapies in Group A ( n = 32); antidiabetic, antihypertensive, and antilipemic therapies in Group B ( n = 32); antidiabetic, antihypertensive, and antilipemic therapies plus Vitamin E in Group C ( n = 32); and antidiabetic, antihypertensive, and antilipemic therapies plus CDDP, 10 pills, three times per day in Group D ( n = 34).
In a multicenter randomized controlled clinical trial involving 744 patients with type 2 diabetes for more than 3 months, background therapy (conventional oral antidiabetics + statins) was administered in the control group and background therapy + CDDP 15 pills, three times per day, were administered in the treatment group.
In a randomized, double-blind, dose parallel, controlled, multicenter clinical trial involving 223 patients with nonproliferative diabetic retinopathy, patients received CDDP treatment at high dose (30 pills three times per day), moderate dose (20 pills three times per day), low dose (10 pills three times per day), and placebo.
In a meta-analysis involving 17 randomized controlled studies, CDDP, as a main intervention, was used for the treatment of diabetic retinopathy in 1050 patients.
So far, three papers on meta-analysis including 47 literatures have been published with 3574 patients on the use of CDDP for the prevention and treatment of diabetic nephropathy.
In a meta-analysis of 19 randomized controlled clinical trials involving 1491 patients, CDDP group ( n = 740) received conventional therapy plus CDDP 10 pills, three times per day, and the control group ( n = 751) received conventional therapy alone.
In another meta-analysis of 14 randomized controlled trials involving 1050 patients, the CDDP combination group had a significantly lower urine microalbumin excretion rate at postdose ( P < 0.001).